亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC

医学 培美曲塞 内科学 肿瘤科 中止 化疗 顺铂
作者
David Planchard,Pasi A. Jänne,Ying Cheng,Chee Khoon Lee,К. К. Лактионов,Tong‐Yuan Yang,Yan Yu,Terufumi Kato,Liyan Jiang,Busyamas Chewaskulyong,Sarayut Lucien Geater,J-M. Maurel,Celeste Rojas,Libor Havel,Frances A. Shepherd,Kentaro Tanaka,Dana Ghiorghiu,Edgar Monterroso,Xiangning Huang,J.C.-H. Yang
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1311-S1312 被引量:2
标识
DOI:10.1016/j.annonc.2023.10.069
摘要

In FLAURA2 (NCT04035486), osi, a 3rd gen CNS-active EGFR-TKI, combined with platinum-pemetrexed (osi-CTx) showed a statistically significant improvement vs osi-monotherapy (osi-mono) in PFS per investigator (HR [95% CI]: 0.62 [0.49–0.79], p<0.001) with a manageable and tolerable safety profile. Addition of CTx did not affect osi exposure. 76% of pts completed 4 CTx cycles; median duration of pemetrexed exposure was 8.3 mos. 40% of FLAURA2 pts had baseline CNS metastases (mets); we report exploratory analyses of CNS efficacy by CNS blinded independent central review (BICR; conducted by neuroradiologist). Updated safety data will be reported. Eligible pts (≥18 y [Japan: ≥20] with EGFRm advanced NSCLC, no prior tx for advanced NSCLC; asymptomatic CNS mets not requiring steroids or stable >2 wks after definitive tx/steroids were allowed) were randomised 1:1 to 1L osi-CTx or osi-mono until progression/discontinuation. Brain imaging (MRI preferred) was performed in all pts at baseline + progression, and at scheduled assessments until progression for pts with baseline CNS mets. CNS endpoints (modified RECIST1.1) included CNS PFS, CNS response and CNS DoR by CNS BICR. Safety was assessed by CTCAE v5. Data cutoff: 3 Apr 2023. Of 557 pts randomised, 118/279 (osi-CTx) and 104/278 (osi-mono) were included in the CNS BICR full analysis set (cFAS; pts with ≥1 measurable and/or non-measurable lesion); 40/118 (osi-CTx) and 38/104 (osi-mono) were included in the CNS evaluable for response set (cEFR; pts with ≥1 measurable lesion). Demographics were balanced across tx arms. CNS efficacy is shown (Table). Safety profile was similar in the cFAS and overall population. The safety and tolerability profile during the course of tx will be described. In FLAURA2, pts with CNS mets in the osi-CTx arm had a clinically meaningful reduction in the risk of CNS progression, with high CNS ORR (and high CR) and durable responses, with a manageable and tolerable safety profile.Table: LBA68cFAScEFROsi-CTx(n=118)Osi-mono(n=104)Osi-CTx(n=40)Osi-mono(n=38)CNS ORR, n (%)86 (73)72 (69)35 (88)33 (87)- CR, n (%)70 (59)45 (43)19 (48)6 (16)Median CNS DoR, mos (95% CI)NR (23.8–NC)26.2 (19.4–NC)NR (21.6–NC)20.9 (12.6–NC)BICR CNS PFS- HR (95% CI)*0.58 (0.33–1.01)0.40 (0.19–0.84)- Median, mos (95% CI)30.2 (28.4–NC)27.6 (22.1–NC)NR (23.0–NC)17.3 (13.9–NC)*Analysed using stratified (cFAS; by race, WHO PS and EGFRm test method) or unstratified (cEFR) log-rank testCR, complete response; DoR, duration of response; NC, not calculable; NR, not reached; ORR, objective response rate; PFS, progression-free survival Open table in a new tab

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
大个的应助被小医采纳,获得10
1秒前
1秒前
王璐雅完成签到 ,获得积分10
2秒前
lengzixing完成签到,获得积分10
3秒前
无情的夏蓉完成签到,获得积分10
3秒前
付一迪完成签到 ,获得积分10
4秒前
4秒前
追风少年的应助被纯情的阁采纳,获得30
4秒前
脑洞疼的应助被纯情的阁采纳,获得10
4秒前
JamesPei的应助被纯情的阁采纳,获得10
4秒前
ayw发布了新的文献求助10
6秒前
高贵嘉懿完成签到,获得积分10
7秒前
跑跑完成签到 ,获得积分10
7秒前
msn00完成签到 ,获得积分10
15秒前
16秒前
谭一谈完成签到,获得积分10
16秒前
水墨丹青完成签到 ,获得积分10
16秒前
徐徐图之完成签到 ,获得积分10
17秒前
刻苦的觅双完成签到,获得积分10
19秒前
小医发布了新的文献求助10
21秒前
23秒前
冇_完成签到 ,获得积分10
23秒前
May完成签到 ,获得积分10
23秒前
北暖完成签到 ,获得积分10
25秒前
THN完成签到,获得积分10
25秒前
ayw完成签到,获得积分10
32秒前
小二郎的应助被纯情的阁采纳,获得10
33秒前
Jasper的应助被纯情的阁采纳,获得10
33秒前
屑面包完成签到,获得积分10
39秒前
40秒前
41秒前
清爽瑛完成签到,获得积分10
41秒前
43秒前
深情大象完成签到,获得积分10
44秒前
45秒前
chenzitong0838完成签到,获得积分10
47秒前
47秒前
mmhk完成签到,获得积分10
52秒前
迷你的雁玉完成签到,获得积分10
56秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554333
关于积分的说明 21718908
捐赠科研通 7748056
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551841
邀请新用户注册赠送积分活动 2471242